Market News

Kybella first FDA-approved non-surgical injection for submental fullness bolsters Allergan's facial aesthetics portfolio.

The FTC filed its amicus brief in a private antitrust action in which Mylan Phamraceuticals Inc. alleges that Warner Chilcott PLC/Mayne Pharma Group maintained a monopoly in the market for its antibiotic Doryx by suppressing generic competition through...

NGF antibody fasinumab currently in Phase II/III osteoarthritis trial.

Demand in Latin America region fuels double-digit sales growth in Q2 2015.

ADCC-enhancement for innovative cancer therapy, produced via ProBioGen’s accelerated CMC development path.

Selected APIs, such as ibuprofen, omega-3 fatty acids and polyethylenglycol (PEG), where the company has a leading market position, will remain a key part of BASF’s portfolio.

The new centre will provide companies with open access facilities and expertise to help them develop, prove and commercialise new and improved processes and technologies for biologics manufacture.

Closing of transaction expected within next 2 months.

Expansion includes a new commercial spray dryer unit, which will be specifically designed to handle potent APIs

Fifth anniversary of the first commercial ADC (Adcetris) sees Piramal introduce ‘Proof of Concept’ service for next wave of ADC growth.

Chemotherapy is evolving to include biomarker-driven remedies based on the molecular mutations of tumours, finds Frost & Sullivan.

Research and Markets announces the addition of the "ADC Contract Manufacturing Market (2nd edition), 2015–2025" report to their offering.

SMEs predicted to be main beneficiaries.

Pending final FDA approval, Basaglar can be launched in the US beginning on 15 December 2016.

Genovate's target is to become China's first and the world's fourth largest insulin manufacturer.

Ruling bars generic versions of Vyvanse from entering market until patents expire.

Allergan is the first company to receive FDA approval for and launch a generic version of Janssen's Invega.

The new outstation will provide life science researchers with the company's proprietary DigiWest multiplex protein profiling services, to accelerate lead characterisation, disease mechanism and drug mode-of-action analyses, as well as biomarker identif...

Technological developments allow the new washers to deliver enhanced drying performance from an upgraded dual fan system incorporated in the washer chambers.

Acquisition will add a leader in pharmaceutical distribution across the Republic of Ireland and Northern Ireland to McKesson’s European business.

The plant will manufacture FlexPen prefilled devices.

The plans include a multifunctional preclinical research facility and a state-of-the-art biologics manufacturing facility.

Envigo has been created through the integration of Huntingdon Life Sciences, Harlan Laboratories, GFA, NDA Analytics and LSR associates.

HHS will provide initial funding of approximately $17 million to support preclinical development and antibody manufacturing. This initial funding is designed to support an Investigational New Drug application with the FDA.

Girish Malhotra believes the pharmaceutical industry should be allowed to commercialise process improvements without regulatory re-approval.

Frost & Sullivan webinar reveals stem cell therapy pipeline and treatments innovating regenerative medicine.

The 5-year base subcontract covers studies to improve the manufacturing process and establish long-term storage of MVA-BN Filo bulk vaccine. The contract also includes options for an additional USD 24 million to implement process development activities...

Pharmaceutical professionals must develop wider commercial and business skills if they want to continue to secure the top jobs, according to NonStop Recruitment.

Dezima's lead molecule is TA-8995, an oral, once-daily cholesteryl ester transfer protein (CETP) inhibitor.

Genevac has developed a suite of proprietary technological solutions to facilitate post purification sample handling, including reformatting.

The terms of the license cover commercial use of a genetically-engineered Chinese Hamster Ovary (CHO) cell line, developed by Horizon and adapted to manufacturing conditions by LakePharma.

The LakeCentre facility, located in Boulder, Colorado will increase manufacturing and production capacity to support the company’s extensive portfolio of biologics medicines.

Industry experts identify and address common problems encountered during modern tablet production from punch and die design, to tooling specification and aftercare.

The investment comes as the CDMO pharmaceutical sector is expected to grow significantly in the next 5 years.

The company’s sepsis therapy has the potential to be used not only in combination with existing antibiotics, but also to treat patients when conventional therapeutic options are not available.